Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease
Inflammatory bowel disease patients treated with biologics or OSM were not at increased risk of MACE or VTE. Although further studies and longer follow-up periods are needed to confirm these findings, our results provide reassurance regarding the safety of these medications in IBD.
Authors
- Ahmad Naser
- Dina Alayan (ORCID: https://orcid.org/0000-0001-9481-2461)
- Mohammed Abu‐Rumaileh (ORCID: https://orcid.org/0000-0002-2691-8974)
- Thabet Qapaja (ORCID: https://orcid.org/0000-0003-4563-3007)
- Miguel D. Regueiro (ORCID: https://orcid.org/0000-0002-7681-8111)
- Khaled Alsabbagh Alchirazi (ORCID: https://orcid.org/0000-0003-0290-9835)
- Ahmad Gharaibeh (ORCID: https://orcid.org/0000-0003-0586-2745)
- Osama Hamid
Institutions
- Aurora Health Care (US)
- MetroHealth (US)
- Cleveland Clinic (US)
- Jacobi Medical Center (US)
- MetroHealth Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Toledo (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1093/ibd/izae267
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10